Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

September 01, 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

March 29, 2025

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

November 11, 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

November 06, 2024

PEERLESS: FlowTriever Tops Catheter-Directed Thrombolysis for Acute PE

News Conference News TCT 2024

PEERLESS: FlowTriever Tops Catheter-Directed Thrombolysis for Acute PE

October 29, 2024

Will IVUS Ever Take Off in Peripheral Vascular Interventions?

News Conference News ISET 2024

Will IVUS Ever Take Off in Peripheral Vascular Interventions?

January 31, 2024

AI in Pulmonary Embolism: ‘Transformative’ for Patient Care

News Conference News ISET 2024

AI in Pulmonary Embolism: ‘Transformative’ for Patient Care

January 30, 2024

Venous Stents: How to Choose Among the Wealth of Options

News Conference News ISET 2024

Venous Stents: How to Choose Among the Wealth of Options

January 26, 2024

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

News Conference News VIVA 2023

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

November 01, 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

August 30, 2023

FLASH: PE Patients Show Ongoing Clinical, QoL Gains With Thrombectomy

News Conference News SCAI 2023

FLASH: PE Patients Show Ongoing Clinical, QoL Gains With Thrombectomy

May 21, 2023

‘Who’s In Charge of a Wound?’: Interventionalists Should Play a Role

News Conference News ISET 2023

‘Who’s In Charge of a Wound?’: Interventionalists Should Play a Role

January 18, 2023

Dedicated Catheter for Acute PE Shows Promise in IDE Trial

News Conference News TCT 2022

Dedicated Catheter for Acute PE Shows Promise in IDE Trial

September 17, 2022

FlowTriever Safe, Effective for Acute PE in Expanded FLASH Results

News Conference News TCT 2021

FlowTriever Safe, Effective for Acute PE in Expanded FLASH Results

November 03, 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

October 08, 2021

FlowTriever Looks Good for Acute PE in Interim FLASH Results

News Conference News TCT 2020

FlowTriever Looks Good for Acute PE in Interim FLASH Results

October 18, 2020

Interventionalists, Including PERTs, Grapple With VTE Risks of COVID-19

News Conference News TCT 2020

Interventionalists, Including PERTs, Grapple With VTE Risks of COVID-19

Michael O'Riordan

October 14, 2020

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

News Conference News HFSA 2020

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

October 12, 2020

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

News Conference News ESC 2020

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

September 04, 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

April 02, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.